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Background: Discrepancies have been observed between clinical, physiological, and inflamma-
tory asthma control criteria, mostly in asthmatic subjects using regular inhaled corticosteroids
(ICS) treatment. This study compared the prevalence of discrepancies between these 3 control
parameters in mild asthmatic subjects not taking ICS.
Methods: A retrospective analysis of demographic data and results from the Asthma Control
Scoring System tool was performed in mild patients with asthma not taking ICS. The % score
obtained for the clinical (symptoms), physiological (FEV1), and inflammatory (sputum eosino-
phil percentage) criteria were compared. Discrepancy was defined as a >20% difference be-
tween any 2 scores.
Findings: Data from 213 subjects with mild asthma were analysed. Discrepancies between clin-
ical and inflammatory scores were observed in 32% of subjects, whereas 31% showed discrep-
ancies between physiological and inflammatory scores, and 20% between clinical and
physiological scores. Sub-analysis of the discrepancy groups showed that respectively 88%
and 89% of subjects had a higher clinical or physiological score than inflammatory score.
Twenty-seven percent of subjects had residual airway inflammation despite adequate clinical
control and optimal pulmonary function.
Interpretation: There are significant discrepancies between scores of subjective and objective
asthma control criteria. Airway inflammation often persists in subjects with good clinical or
physiological asthma control scores. The consequences of this persisting airway inflammation
in mild patients remain to be further studied.
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be present in these subjects.16 Still, the prevalence of theseAsthma is a multi-faceted disease, characterised by symp-
toms, variable airflow obstruction, and lower airway
inflammation. Current guidelines suggest that the main goal
of asthma treatment should be an adequate control of the
disease1,2 and a reduction in future risk of exacerbations.3
Until recently, asthma control was mostly defined accord-
ing to subjective clinical features such as daytime and
nighttime symptoms, rescue beta-2-agonist need, the
ability to perform normal activities, absenteeism from work
or school, and the severity and frequency of asthma exac-
erbations, and objective physiologic measures of expiratory
flows.1,2 Measurement of airway inflammation is increas-
ingly considered useful in the management of asthma and
the most recent Canadian Asthma Consensus Report rec-
ommends that sputum eosinophil measurement be inclu-
ded, in addition to standard measures of asthma control, to
guide adjustment of controller therapy in adults with
moderate to severe asthma, in centres where this techni-
que is available.4 We need however to better assess dis-
crepancies between the 3 key components of asthma and
determine what is the significance of those differences in
regard to asthma management.
Discordance between clinical and physiological mea-
sures of asthma control have been previously studied.5
More recently, a lack of concordance between lower air-
way inflammation and clinical asthma control parameters
or pulmonary function has also been described6e11 and re-
sidual eosinophilic airway inflammation has been asso-
ciated with an increased risk of future asthma
exacerbations in moderate/severe asthma.12,13 However,
these studies have been performed mostly in subjects using
inhaled corticosteroids (ICS).
Subjectswithmildpersistentasthmaformthe largest group
of asthma patients14 and although they are well clinically
controlled, they can experience asthma exacerbations.15Figure 1 Visual representation of the number of patienDespite no or few symptoms, lower airway inflammation may
discrepancies and their impact on asthmacontrol has notbeen
determined in this population nor have potential long-term
consequences of this feature been properly assessed.
The Asthma Control Scoring System (ACSS) is based on
the asthma control criteria proposed by the Canadian
Asthma Consensus Report,17 these criteria being relatively
close to those proposed by the Global initiative for Asthma
(GINA).2 It is a validated tool, that showed adequate
measurement properties, both as an evaluative and as
a discriminative instrument.18 The ACSS is a composite
score and it may therefore be useful to explore, quantita-
tively, discrepancies between the various manifestations of
asthma and better define clinical phenotypes to help guide
therapeutic decisions.
In this study, we looked at the prevalence and de-
terminants of discrepancies between clinical, physiologi-
cal, and inflammatory asthma control criteria, as
reported by the ACSS, in mild asthmatic subjects not
taking ICS.
Methods
Subjects and study design
This is an analysis of data from subjects presenting for
initial assessment of asthma at the outpatient clinic of the
Institut universitaire de cardiologie et de pneumologie de
Que´bec or willing to take part to various studies on asthma
pathophysiology and treatment, between 2003 and 2010
(Fig. 1). Data from subjects over 18 years old with a diag-
nosis of asthma, as defined by the Canadian Asthma Con-
sensus Guidelines1 for which the 4 clinical control
parameters of the ACSS were documented, spirometry was
performed (to provide a measure of FEV1), and sputum in-
duction with sufficient material for adequate analysis wasts who were screened and who completed the study.
Discrepancies between asthma control criteria 513obtained were considered. These subjects were not using
ICS or any other bronchial anti-inflammatory treatment.
The study was reviewed and approved by the local Insti-
tutional Ethics Committee (CER 20785).Asthma Control Scoring System (ACSS)
Three types of parameters can be evaluated using the ACSS:
clinical (diurnal symptoms, nocturnal symptoms, rescue
beta-2-agonists use, activities), physiological (forced
expiratory volume in one second (FEV1) and/or peak
expiratory flows (PEF), and/or PEF circadian variations)
and, as an option, lower airway inflammation (induced
sputum eosinophilia). The first section of the questionnaire
(clinical parameters) is filled according to the patient’s
report, in reference to his/her last week experience,
whereas the second and third sections are completed ac-
cording to the results obtained from additional tests at the
time of assessment. The three sections are quantified to
obtain a total score of 100% each and a global score is
determined using the mean score of the equally weighted
sections filled (100% Z very well controlled and 0% Z not
controlled at all). It should be remembered that high
symptoms, low pulmonary function, and high eosinophil
counts are resulting in a low score. For the purpose of this
study, the 3 sections of the questionnaire had to be filled
for a subject to be included and FEV1 was used as the
physiological parameter.Spirometry
Spirometry was performed according to the recommenda-
tions of the American Thoracic Society.19 The best pre-
bronchodilator FEV1 of 3 reproducible values was recor-
ded and percent predicted was used as the physiological
parameter of the ACSS. Predicted values were obtained
from Knudson.20Induced sputum
Sputum was induced using the method described by Pin
et al.21 and modified by Pizzichini et al.22 A differential cell
count, including eosinophils, neutrophils, macrophages,
lymphocytes, and bronchial cells, was performed by an
experienced technician (>10 years sputum cell counting
experience).Definitions
Discrepancy
Discrepancy was arbitrarily defined as a >20% difference
between any 2 scores, corresponding to one subdivision of
the ACSS which is based on the Canadian Asthma
Guidelines.1
Control
Controlled asthma was defined as an ACSS global score
80%, in keeping with the Canadian Guidelines
recommendations.1Mild asthma
Subjects were included as mild asthmatics if they had very
mild asthma, not requiring ICS regularly, or mild asthma
that may have needed ICS treatment but that were not
using them at the time of the initial evaluation.
Eosinophilic inflammation
Eosinophilic inflammation was defined as a sputum eosino-
phil count >2%.23Statistical analysis
Data were expressed as means  SD or as numbers for
categorical data. The analyses of categorical variables
were performed using Chi-Square or Fisher’s exact test.
For continuous data, one-way ANOVA was fitted to compare
groups with heterogeneous variances and, when appli-
cable, the model was reduced to a one-way analysis with
the same variance across groups. Reported p-values are
based on this transformation. Posteriori comparisons were
performed using the Tukey’s comparison technique. The
univariate normality assumptions were verified with the
ShapiroeWilk tests. The results were considered significant
with p-values 0.05. All analyses were conducted using the
statistical package SAS v9.2 (SAS Institute Inc, Cary, NC,
U.S.A.).Results
Subjects’ characteristics
Data from 213 (122F/91M) mild asthmatic subjects not
taking ICS were analysed. Clinical characteristics of the
whole sample and subsamples are shown in Table 1. About
one-third of subjects had discrepancies between clinical or
physiological score and inflammatory score, whereas 20%
had discrepancy between clinical and physiological scores.
The various discrepancy groups did not differ in gender,
mean age, duration of asthma, atopy, ACSS global score,
FEV1, or BMI.
Sub-analysis of the discrepancy groups showed that
more subjects had a higher (better) clinical or physiolog-
ical score than inflammatory score (60 (88%) vs 8 (12%) and
59 (89%) vs 7 (11%), respectively) (Fig. 2). Among subjects
with a lower clinical score and a higher physiological or
inflammatory score (considered as low perceivers), there
were significantly more women than men (data not
shown). There were no other significant differences in the
characteristics of the subjects according to the higher
score.
Since subjects could be in more than one discrepancy
group, data were analysed according to the number of
discrepancies (Table 2). Subjects did not differ in their
clinical characteristics according to the number of dis-
crepancies, except for the ACSS global score, which was
significantly higher in subjects without discrepancy
whereas subjects with 3 discrepancies had a significantly
lower ACSS global score. Subjects having 2 discrepancies or
more had significantly more eosinophils than subjects
without discrepancy.
Table 1 Clinical characteristics of the total sample and subsamples.
All subjects Subjects without
discrepancy
Mean diff > 20% p
C vs I P vs I C vs P
n [%] 213 114 [53] 68 [32] 66 [31] 42 [20]
Gender (F/M) 122/91 61/53 44/24 44/22 21/21 NS
Age (years)a 31  10 31  10 32  10 32  10 32  9 NS
Duration of asthma (years)a 16  10 16  10 16  11 16  11 15  9 NS
Atopy (yes/no) 189/213 101/12 63/3 59/5 35/5 NS
ACSS global score (%)a 82  11 89  8b 74  10 74  10 74  11 NS
Mean difference (%)a 46  18 52  16 34  10
FEV1 (% pred.)
a 96  16 98  16 96  15 96  16 91  18 NS
BMI (kg/m2)a 26  7 27  8 28  6 28  6 28  6 NS
Smoking (S/Ex/NS) 42/30/141 20/14/80 8/12/48 12/13/41 15/4/23 NS
Sputum eosinophils (%)a 4.0  9.0 1.1  2.8 8.9  10.1 8.7  10.0 6.3  14.0 <0.0001b
Sputum neutrophils (%)a 34.0  23.0 33.8  23.9 34.2  20.9 32.0  21.6 40.4  23.1 NS
C: clinical score, P: physiological score, I: inflammatory score, F: female, M: male, FEV1: forced expiratory volume in one second, BMI:
body.
a Mean  SD.
b Subjects without discrepancy vs all the other groups with discrepancy.
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discrepancies
Data were analysed according to the level of control
(Table 3). There were 145 (68%) subjects in the controlled
group (ACSS global score 80%) and 68 (32%) subjects in the
uncontrolled group (ACSS global score <80%). Particularly,
7 subjects showed total control, with an ACSS score of 100%
(data not shown). There were significantly more subjects
with discrepancies in the uncontrolled group than in the
controlled group.
Interestingly, more than half of the subjects with an
ACSS score <80% had a clinical score 80% and more than
60% had a physiological score 80%, whereas only about
a third of these subjects had an inflammatory score 80%.Clinical and physiological scores in relation to
sputum eosinophils
When the mean clinical þ physiological score was analysed
according to sputum eosinophil percentages, 27% of sub-
jects had inflammation (>2% eosinophils) even though their
mean clinical þ physiological score was 80% (Fig. 3).Figure 2 Discrepancy distribution according to the higher score. A
shows the percentage of subjects for which one score was higher in
C: Clinical score, P: Physiological score, I: Inflammatory score.Discussion
This study is, to our knowledge, the first to report the
prevalence of discrepancies between clinical, physiologi-
cal, and inflammatory asthma control criteria in mild
asthmatic subjects not taking inhaled corticosteroids. The
key messages of this analysis are that: 1) such discrepancies
are common in mild asthma as reported in more severe
asthma, 2) there are no specific subject characteristics
which can help identify those with such discrepancies,
and 3) the prevalence of residual airway inflammation
despite good clinical control is high in this population. This
brings 2 important questions to answer: 1) What are the
long-term consequences of such unantagonised airway
inflammation and 2) Should these results change our
approach to mild asthma and lead to earlier introduction of
anti-inflammatory agents, despite minimal symptoms and
excellent airway function?
Using the ACSS, we found that a third of asthmatic
subjects had discrepancies between inflammatory score
and clinical or physiological scores. Among these, about
90% had a better clinical or physiological score than in-
flammatory score, suggesting that although control seems
adequate according to symptoms or expiratory flows,mong subjects that had >20% difference between 2 scores, this
grey and subjects for which the other score was higher in white.
Table 2 Clinical characteristics of subjects according to the number of discrepancies.
Number of discrepancies
0 1 2 3
n [%] 114 [53] 29 [14] 63 [30] 7 [3]
Gender (F/M) 61/53 16/13 39/24 5/2
Age (years)a 31  10 30  10 32  10 29  6
Duration of asthma (years)a 16  10 16  11 16  11 15  9
Atopy (yes/no) 101/12 25/3 57/5 6/0
ACSS global score (%)a 89  8b 78  8 75  10 63  6b
FEV1 (% pred.)
a 98  16 92  16 95  16 98  23
BMI (kg/m2)a 27  8 27  7 26  6 25  4
Smoking (S/Ex/NS) 20/14/80 11/3/15 9/13/41 2/0/5
Sputum eosinophils (%)a 1.1  2.8 4.2  13.7 7.5  9.0c 17.8  14.3b
Sputum neutrophils (%)a 33.8  23.9 37.5  23.8 33.5  20.6 34.9  28.4
F: female, M: male, FEV1: forced expiratory volume in one second, BMI: body mass index, S: smokers, Ex: ex smokers, NS: non-smokers.
a Mean  SD.
b p < 0.003 vs all the other groups.
c p < 0.0001 vs 0 discrepancy.
Discrepancies between asthma control criteria 515underlying inflammation often persists. In addition, there
are significantly more subjects showing discrepancies be-
tween the various asthma control parameters in a group of
patients whose asthma was deemed uncontrolled according
to the ACSS.Table 3 Characteristics of subjects according to the level
of asthma control as assessed by the ACSS.
Parameter Global
score  80%
Global
score < 80%
p
n 145 68
Gender (F/M) 86/59 35/33 NS
Age (years)a 31  10 32  9 NS
Duration of asthma
(years)a
16  10 16  10 NS
FEV1 (% pred.)
a 100  14 87  17 <0$0001
BMI (kg/m2)a 27  7 26  5 NS
Smoking (S/Ex/NS) 20/20/105 22/9/37 0$005
ACSS global score (%)a 89  6 69  9
Clinical score 80%
(n [%])
131 [90%] 36 [53%] <0$0001
Physiological score 80%
(n [%])
142 [98%] 42 [62%] <0$0001
Inflammatory score 80%
(n [%])
118 [81%] 21 [31%] <0$0001
>20% difference C vs I
(n [%])
25 [17%] 43 [63%] <0$0001
>20% difference P vs I
(n [%])
27 [19%] 39 [57%] <0$0001
>20% difference C vs P
(n [%])
16 [11%] 26 [38%] <0$0001
Sputum eosinophils (%)a 2  7 8  10 <0$0001
Sputum neutrophils (%)a 34  25 35  19 NS
C: clinical score, P: physiological score, I: inflammatory score,
F: female, M: male, FEV1: forced expiratory volume in one
second, BMI: body mass index, S: smokers, Ex: ex smokers, NS:
non-smokers.
a Mean  SD.The relationships between clinical, physiological and,
more recently, inflammatory asthma control parameters
have been assessed in the global asthma population, par-
ticularly in moderate-to-severe asthmatics taking ICS as
their regular medication.5e11 In this regard, Bora et al.
found, following an analysis of data from 83 patients with
asthma, that Asthma Control Test (ACT) scores did not
show significant correlations with the airway inflammatory
parameters.24 Moreover, in a study exploring the analysis of
induced sputum and asthma control status, as also deter-
mined by the ACT, Shiota et al. observed, in 101 patients
with chronic asthma, that the asthma control score was
not associated with airway eosinophilic or neutrophilic
inflammation. However, the frequency of nocturnal symp-
toms was associated with sputum eosinophilia and the
frequency of rescue SABA use was associated with sputum
neutrophilia.10
As mild asthmatics represent the most important pro-
portion of asthmatic patients14 they are a potential target
for preventive strategies against disease progression. Dis-
crepancies between asthma control parameters have been
associated with an increased risk of asthma exacerbations
in moderate to severe asthmatics.12,13 Although we do not
know yet the involvement of such discrepancies and their
possible role in asthma exacerbations in mild asthmatic
subjects, identifying those showing discrepancies might be
a first step in optimal management of the disease.
We found a high prevalence of subjects with no or few
symptoms (high clinical score) or normal expiratory flows
(high physiological score), but with high sputum eosinophil
percentages (low inflammatory score). In addition, when
eosinophil percentages were plotted against the mean
percentage of clinical and physiological scores, almost one
third of subjects showed increased eosinophil percentages
(>2%) even though their level of control seemed adequate
according to clinical and physiological scores (>80%). In
mild asthmatic subjects not taking ICS, symptom percep-
tion is often inaccurate whether it is assessed by patients
or physicians.25 Since asthma is often mainly managed
according to this parameter, failure to adequately
Figure 3 Percentage of sputum eosinophils in relation to the mean clinical þ physiological score. Although
clinical þ physiological score is 80%, 27% of subjects still have more than 2% sputum eosinophils.
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treatment for patients with a poor perception of symp-
toms, leading to potentially avoidable morbidity and
mortality.26 Studies on follow-up strategies have shown
that sputum eosinophilia, exhaled nitric oxide, or airway
responsiveness are more effective than symptom scores in
reducing the number of exacerbations and hospital visits,
particularly in moderate to severe asthma.27e29 In patients
with mild persistent asthma, rates of severe asthma ex-
acerbations, if untreated, are higher than expected,
although the usefulness of sputum eosinophilia to guide
therapy in this group of mild asthmatic subjects has not
been demonstrated.
Although monitoring airway inflammation in steroid-
naı¨ve asthmatic patients does not seem to reduce asthma
exacerbations, persistent eosinophilia has been associated
with an accelerated decline in lung function and the
development of fixed airway obstruction, possibly following
airway remodelling.30 It is possible that persistent un-
treated eosinophilia leads to progressive remodelling and
chronic changes in airway function. We previously showed
that patients with long standing mild steroid-naive asthma
had increased airway hyperresponsiveness compared to
those with more recently diagnosed asthma, whereas they
had the same degree of improvement in airway respon-
siveness after high-dose inhaled corticosteroids, suggesting
permanent non-inflammatory changes in their airways.31
Furthermore, early intervention with budesonide has been
shown to decrease the risk of severe asthma exacerbation
and to improve asthma control in adults and children with
mild persistent asthma.32,33 We know little about the long
term effects of airway eosinophilia, as these patients do
not usually have non-invasive measures of airway inflam-
mation and are seen in primary care. Further research is
therefore needed on this.
In the present study, ACSS global score was significantly
higher in subjects without discrepancies and significantly
lower in subjects with 3 discrepancies. Moreover, when
data were analysed according to the level of asthma con-
trol, there were significantly more subjects with discrep-
ancies in the uncontrolled group as compared to thecontrolled one. This suggests that discrepancies between
asthma control parameters have an impact on asthma
control, but whether this represents a marker of future risk
needs to be further determined in a longitudinal study,
particularly in mild patients, even if those events are less
frequent.
Our study had some limitations. First, the use of a per-
centage of predicted FEV1 could have underestimated the
level of control compared with the percentage of optimal
individual FEV1 since it does not take the component of
fixed airflow obstruction in consideration. However, in our
cohort of mild asthmatics, fixed airway obstruction was
very uncommon; this may be more relevant in more severe
patients.
The physiological measurement of the ACSS can either
be FEV1 or PEF. We chose to use the FEV1 as it is more
commonly measured in baseline assessment evaluation
(either for a research project or in the clinic). Validation
study of the ACSS showed good internal consistency for the
physiologic section, suggesting that both FEV1 and PEF can
be used separately.18 Furthermore, comparison of the
measurement properties of daily diary (using a modified
diary version of the Asthma Control Questionnaire (ACQ)) vs
the ACQ by Juniper et al. showed that there was no sig-
nificant difference between group PEF daily measurements
and single clinic FEV1% predicted measurement.
34
The minimal clinically important difference of the ACSS
has not been determined and discrepancy was therefore
defined as a 20% difference between 2 scores. This corre-
sponds to one subdivision of the ACSS which is based on the
clinical status according to the Canadian Asthma Guide-
lines.1 In addition, it is in keeping with the minimal clin-
ically important difference in other validated asthma
control tools.35,36
Likewise, the cut-off value to separate controlled and
uncontrolled subjects according to the ACSS global score
has not been determined and an 80% score was chosen
according to current control criteria. The various compo-
nents corresponding to this score are based on the asthma
control criteria as determined by the Asthma Consensus
Report.1
Discrepancies between asthma control criteria 517In conclusion, this study shows that discrepancies be-
tween clinical, physiological and inflammatory parame-
ters of asthma control are frequent in mild asthmatic
subjects not under ICS treatment. These discrepancies are
highly prevalent in subjects with uncontrolled asthma.
Although clinical or physiological scores seem adequate,
underlying inflammation often persists. This stresses the
need to assess the various components of asthma, as their
evaluation may lead to a more appropriate asthma
treatment, therefore potentially reducing asthma mor-
bidity. The long-term effects of treating according to the
various sets of parameters should be very instructive in
this regard.
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